{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER-2+Positive+Breast+Cancer&page=7", "query": { "condition": "HER-2 Positive Breast Cancer", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 856, "total_pages": 86, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER-2+Positive+Breast+Cancer&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HER-2+Positive+Breast+Cancer&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T12:50:24.636Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07060807", "title": "A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "BIOLOGICAL" }, { "name": "Rescue Medication", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1000, "start_date": "2025-07-21", "completion_date": "2033-07-14", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 35, "location_summary": "Daphne, Alabama • Tucson, Arizona • Los Angeles, California + 28 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Grand Junction", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07060807" }, { "nct_id": "NCT00433407", "title": "T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Ovarian Cancer", "Prostate Cancer", "Sarcoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 12, "start_date": "2005-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00433407" }, { "nct_id": "NCT02007512", "title": "Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "exemestane", "type": "DRUG" }, { "name": "Placebo (for enzalutamide)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 247, "start_date": "2013-12-16", "completion_date": "2024-08-23", "has_results": true, "last_update_posted_date": "2025-09-02", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 89, "location_summary": "Aurora, Colorado • Colorado Springs, Colorado • Lakewood, Colorado + 54 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Lakewood", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02007512" }, { "nct_id": "NCT06671912", "title": "Testing Low Dose Tamoxifen for Invasive Breast Cancer, LoTam Trial", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anatomic Stage 0 Breast Cancer AJCC v8", "Anatomic Stage 1 Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Estrogen Receptor-Positive Breast Carcinoma", "HER2-Negative Breast Carcinoma", "Breast Ductal Carcinoma In Situ", "Breast Lobular Carcinoma In Situ" ], "interventions": [ { "name": "Anastrozole", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Tamoxifen", "type": "DRUG" }, { "name": "Mammogram", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Dual X-ray Absorptiometry", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1556, "start_date": "2025-02-19", "completion_date": "2031-11-30", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 728, "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Goodyear, Arizona + 559 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06671912" }, { "nct_id": "NCT07701941", "title": "A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone Receptor Positive", "HER2-low or HER2-ultralow", "Unresectable or Metastatic Breast Cancer" ], "interventions": [ { "name": "Patritumab deruxtecan", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2026-09-17", "completion_date": "2032-05-01", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 12, "location_summary": "Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07701941" }, { "nct_id": "NCT03523195", "title": "Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage IIA Breast Cancer AJCC v8", "Anatomic Stage IIB Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Cancer Survivor", "Estrogen Receptor Positive", "HER2/Neu Negative", "Progesterone Receptor Positive", "Prognostic Stage II Breast Cancer AJCC v8", "Prognostic Stage IIA Breast Cancer AJCC v8", "Prognostic Stage IIB Breast Cancer AJCC v8", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Sedentary Lifestyle" ], "interventions": [ { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Informational Intervention", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Monitoring Device", "type": "DEVICE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Physical Performance Testing", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER", "DEVICE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "19 Years to 64 Years" }, "enrollment_count": 20, "start_date": "2018-04-18", "completion_date": "2019-07-15", "has_results": false, "last_update_posted_date": "2019-07-22", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03523195" }, { "nct_id": "NCT00022672", "title": "A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "trastuzumab (Herceptin®)", "type": "DRUG" }, { "name": "anastrazole (Arimidex®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 208, "start_date": "2001-01", "completion_date": "2009-10", "has_results": true, "last_update_posted_date": "2013-06-13", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Gainsville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00022672" }, { "nct_id": "NCT00524277", "title": "Vaccine Therapy in Treating Patients With Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "GP2 peptide + GM-CSF vaccine", "type": "BIOLOGICAL" }, { "name": "GM-CSF (sargramostim)", "type": "BIOLOGICAL" }, { "name": "AE37 + GM-CSF vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "San Antonio Military Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 456, "start_date": "2007-01", "completion_date": "2017-03-31", "has_results": false, "last_update_posted_date": "2020-03-30", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 11, "location_summary": "Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 7 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00524277" }, { "nct_id": "NCT03251378", "title": "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Colon Cancer", "Metastatic Breast Cancer", "Triple Negative Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Rectal Cancer" ], "interventions": [ { "name": "Fruquintinib (HMPL-013)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2017-12-11", "completion_date": "2023-03-30", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 9, "location_summary": "Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Marcos", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03251378" }, { "nct_id": "NCT07506876", "title": "Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer - Infiltrating Ductal Carcinoma", "HER-2 Positive Breast Cancer" ], "interventions": [ { "name": "Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Legacy Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-04-27", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-11-15T12:50:24.636Z", "location_count": 4, "location_summary": "Gresham, Oregon • Portland, Oregon • Tualatin, Oregon + 1 more", "locations": [ { "city": "Gresham", "state": "Oregon" }, { "city": "Portland", "state": "Oregon" }, { "city": "Tualatin", "state": "Oregon" }, { "city": "Vancouver", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07506876" } ] }